NCT01638247 - Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Male Breast Cancer

Interventions

DRUG

Tamoxifen

25 mg daily.

DRUG

Tamoxifen and GnRH analogue

"25 mg Tamoxifen daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."

DRUG

Exemestane and GnRH analogue

"25 mg Exemestane daily and GnRH analogue:~* Goserelin (10.8 mg s.c. after randomisation and after three months) or~* Leuprorelin (11.25 mg s.c. after randomisation and after three months)."

Trial Locations (1)

45136

Kliniken Essen-Mitte, Essen